诺沃诺迪斯克公司以低于美国的价格 推出肥胖药物 Wegovy in China, Wegovy, 价格比美国低。 Novo Nordisk launches obesity drug Wegovy in China at prices lower than in the U.S.

诺沃·诺迪斯克(Novo Nordisk)以大大低于美国的价格在中国推出其销售量最高的肥胖药物韦戈维(Wegovy), Novo Nordisk has launched Wegovy, its top-selling obesity drug, in China at prices significantly lower than in the US. 初始处方将在上海提供,尽管该药不在中国国家健康保险范围内。 Initial prescriptions will be available in Shanghai, though the drug is not covered by China's national health insurance. Wegovy的第三季度销售额为Novo Nordisk带来了25亿美元,该公司正在探索如何使中国的药品更能负担得起,包括通过商业保险。 Wegovy's third-quarter sales brought in $2.5 billion for Novo Nordisk, and the company is exploring ways to make the drug more affordable in China, including through commercial insurance.